Technology Hardware and Equipment

India Jitendra Singh Tender

📄 Tender ID: 483565251 📅 Published: 23 Jan 2023

📋 Tender Overview

Union Minister of State Independent Charge Science Technology Minister of State Independent Charge Earth Sciences MoS PMO Personnel Public Grievances Pensions Atomic Energy and Space Dr Jitendra Singh has lauded Team Biotech for the worlds first Nasal Vaccine.He said as Minister Incharge Science Technology he was proud of the fact that the Department of Biotechnology DBT under the Ministry and its PSU Biotechnology Industry Research Assistance BIRAC had made the major contribution in developing the worlds first Intranasal vaccine for Covid through Bharat Biotech International Limited BBIL.Dr Jitendra Singh gave full credit to Prime Minister Narendra Modi for making this possible and said PM Modis personal intervention and regular monitoring inspired and enabled the launching of Mission Covid Suraksha which has not only strengthened AtmaNirbhar Bharat but also bolstered Indias status as a worldwide vaccine development and manufacturing centre thus showcasing the strength of Indias Science and Technology capabilities. It is a moment of great pride for every Indian he said.The Minister elaborated that the product development and clinical trials were funded by the Department of Biotechnology and BIRAC under Mission Covid Suraksha. This vaccine received approval under restricted use in emergency situations for ages 18 and above for primary two-dose schedule homologous booster doses he added.National Institute of Immunology NII New Delhi an autonomous institute under the Department of Biotechnology utilised its Human Immune Monitoring and T-cell Immunoassay Platform to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses in the trial participants.Interactive Research School for Health Affairs IRSHA Pune supported by DBT BIRAC completed the Plaque Reduction Neutralization Assay PRNT to quantify the titer of neutralising antibodies for the virus from three trial sites.The vaccine is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in Phases I II and III clinical trials with successful results. It has been specifically formulated to allow intranasal delivery through nasal drops. The vaccine is stable at 2-8C for easy storage and distribution.Pertinent to mention that earlier ZyCoV-D the worlds first and Indias indigenously developed DNA based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above was also developed in partnership with the Department of Biotechnology DBT in the Ministry of Science Technology under Mission Covid Suraksha through BIRAC a PSU of DBT.

🔍 Key Information

📄
Tender Reference No.
483565251
📅
Publication Date
23 Jan 2023
🌐
Sector
Technology Hardware and Equipment
📝
Notice Type
News
📍
Location
India

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 23 Jan 2023
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country India
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…